Hunan Nucien Pharmaceutical Co (SHSE:688189) ROIC %: -10.47% (As of Mar. 2026)


SHSE:688189 Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
52 GF Score
Price ¥6.53
GF Value ¥2.36
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Hunan Nucien Pharmaceutical Co ROIC %?

Hunan Nucien Pharmaceutical Co SHSE:688189 +2.03% 52 ROIC % is -10.47% as of Mar. 2026. GuruFocus rates SHSE:688189 with a GF Score™ of 52/100 and a GF Value™ of ¥2.36 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Hunan Nucien Pharmaceutical Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -10.47%.

As of today (2026-07-06), Hunan Nucien Pharmaceutical Co's WACC % is 13.01%. Hunan Nucien Pharmaceutical Co's ROIC % is -14.79% (calculated using TTM income statement data). Hunan Nucien Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Hunan Nucien Pharmaceutical Co  (SHSE:688189) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Hunan Nucien Pharmaceutical Co's WACC % is 13.01%. Hunan Nucien Pharmaceutical Co's ROIC % is -14.79% (calculated using TTM income statement data). Hunan Nucien Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Hunan Nucien Pharmaceutical Co ROIC % Related Terms


Hunan Nucien Pharmaceutical Co ROIC % Historical Data

* Premium members only.

The historical data trend for Hunan Nucien Pharmaceutical Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Nucien Pharmaceutical Co ROIC % Chart

Hunan Nucien Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.81 5.56 3.95 -9.41 -14.07

Hunan Nucien Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.83 -15.59 -14.65 -17.25 -10.47

SHSE:688189 vs ZTS, UTHR: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Nucien Pharmaceutical Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Nucien Pharmaceutical Co ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Nucien Pharmaceutical Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Hunan Nucien Pharmaceutical Co's ROIC % falls into.


SHSE:688189
52GF Score
Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hunan Nucien Pharmaceutical Co ROIC % Calculation

Hunan Nucien Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-78.244 * ( 1 - 0% )/( (674.995 + 437.059)/ 2 )
=-78.244/556.027
=-14.07 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1222.438 - 108.946 - ( 490.27 - max(0, 339.853 - 778.35+490.27))
=674.995

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=809.472 - 70.894 - ( 301.519 - max(0, 93.521 - 399.827+301.519))
=437.059

Hunan Nucien Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-47.02 * ( 1 - 2.03% )/( (437.059 + 443.121)/ 2 )
=-46.065494/440.09
=-10.47 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=809.472 - 70.894 - ( 301.519 - max(0, 93.521 - 399.827+301.519))
=437.059

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=786.702 - 65.494 - ( 278.087 - max(0, 88.787 - 375.634+278.087))
=443.121

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -10.47% mean?
Hunan Nucien Pharmaceutical Co (SHSE:688189) has a ROIC % of -10.47% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Hunan Nucien Pharmaceutical Co and its competitors.
Is Hunan Nucien Pharmaceutical Co's ROIC % too high?
Hunan Nucien Pharmaceutical Co's current ROIC % is -10.47%. Overall, Hunan Nucien Pharmaceutical Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Nucien Pharmaceutical Co's ROIC % compare to ZTS and UTHR?
Hunan Nucien Pharmaceutical Co's ROIC % of -10.47% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.50, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Hunan Nucien Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Nucien Pharmaceutical Co's current ROIC % is -10.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Nucien Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co (SHSE:688189) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.36, compared to a current price of ¥6.53 — trading 176.7% above its estimated fair value. The current ROIC % is -10.47%. Hunan Nucien Pharmaceutical Co's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Hunan Nucien Pharmaceutical Co (SHSE:688189), the current ROIC % is -10.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hunan Nucien Pharmaceutical Co (SHSE:688189) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥6.53 is trading 176.7% above its estimated GF Value™ of ¥2.36. GuruFocus considers Hunan Nucien Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:688189:

  • ROIC %: -10.47%
  • GF Value™: ¥2.36 vs. price of ¥6.53 (176.7% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hunan Nucien Pharmaceutical Co Business Description

Address No. 1 Kangli Road, Liuyang Economic and Technological Development Zone, Hunan Province, Changsha, CHN, 510100
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
52GF Score

Get the complete analysis for SHSE:688189

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.53
Price
¥2.36
GF Value